These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 36448672)

  • 1. New therapies for obesity.
    Papamargaritis D; le Roux CW; Holst JJ; Davies MJ
    Cardiovasc Res; 2024 Feb; 119(18):2825-2842. PubMed ID: 36448672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A new era for glucagon-like peptide-1 receptor agonists].
    Neuville MF; Paquot N; Scheen AJ
    Rev Med Liege; 2023 Jan; 78(1):40-45. PubMed ID: 36634066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the pipeline for future medications for obesity?
    Melson E; Ashraf U; Papamargaritis D; Davies MJ
    Int J Obes (Lond); 2024 Feb; ():. PubMed ID: 38302593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future therapies for obesity.
    Melson E; Miras AD; Papamargaritis D
    Clin Med (Lond); 2023 Jul; 23(4):337-346. PubMed ID: 37524416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [GLP-1 and GIP receptor agonists: emerging therapies for obesity].
    Chartoumpekis D; Favre L
    Rev Med Suisse; 2023 Mar; 19(819):555-561. PubMed ID: 36950785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor poly-agonists: a new era in obesity pharmacotherapy.
    Malik IO; Petersen MC; Klein S
    Obesity (Silver Spring); 2022 Sep; 30(9):1718-1721. PubMed ID: 35872608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-obesity drugs : from previous disappointments to new hopes].
    Scheen A; De Flines J; Paquot N
    Rev Med Liege; 2023 Mar; 78(3):147-152. PubMed ID: 36924152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
    Pedrosa MR; Franco DR; Gieremek HW; Vidal CM; Bronzeri F; de Cassia Rocha A; de Carvalho Cara LG; Fogo SL; Eliaschewitz FG
    Curr Atheroscler Rep; 2022 Nov; 24(11):867-884. PubMed ID: 36044100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on peptide-based therapies for type 2 diabetes and obesity.
    Bailey CJ; Flatt PR; Conlon JM
    Peptides; 2023 Mar; 161():170939. PubMed ID: 36608818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.
    Alkhezi OS; Alahmed AA; Alfayez OM; Alzuman OA; Almutairi AR; Almohammed OA
    Obes Rev; 2023 Mar; 24(3):e13543. PubMed ID: 36579723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into the treatment of obesity.
    Blüher M; Aras M; Aronne LJ; Batterham RL; Giorgino F; Ji L; Pietiläinen KH; Schnell O; Tonchevska E; Wilding JPH
    Diabetes Obes Metab; 2023 Aug; 25(8):2058-2072. PubMed ID: 37055715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
    Nauck MA; D'Alessio DA
    Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.
    D'Ascanio AM; Mullally JA; Frishman WH
    Cardiol Rev; 2024 Jan-Feb 01; 32(1):83-90. PubMed ID: 36883831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.
    Ard J; Fitch A; Fruh S; Herman L
    Adv Ther; 2021 Jun; 38(6):2821-2839. PubMed ID: 33977495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
    De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
    Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
    Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.
    Herrou J; Mabilleau G; Lecerf JM; Thomas T; Biver E; Paccou J
    Calcif Tissue Int; 2024 Feb; 114(2):86-97. PubMed ID: 37999750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.
    Lin CH; Shao L; Zhang YM; Tu YJ; Zhang Y; Tomlinson B; Chan P; Liu Z
    Expert Opin Pharmacother; 2020 Feb; 21(3):275-285. PubMed ID: 31790314
    [No Abstract]   [Full Text] [Related]  

  • 20. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
    Frías JP
    Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.